These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10211097)

  • 1. Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2.
    Hillgenberg M; Schlehofer JR; von Knebel Doeberitz M; Klein-Bauernschmitt P
    Eur J Cancer; 1999 Jan; 35(1):106-10. PubMed ID: 10211097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells.
    Klein-Bauernschmitt P; von Knebel Doeberitz M; Ehrbar M; Geletneky K; Kleinschmidt J; Schlehofer JR
    Eur J Cancer; 1996 Sep; 32A(10):1774-80. PubMed ID: 8983289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP; Ou X
    Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
    Arvelo F; Poupon MF; Bichat F; Grossin F; Bourgeois Y; Jacrot M; Bastian G; Le Chevalier T
    Eur J Cancer; 1995 Oct; 31A(11):1862-8. PubMed ID: 8541114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
    Arvelo F; Poupon MF; Goguel AF; Lizard G; Bourgeois Y; Arriagada R; Le Chevalier T
    J Cancer Res Clin Oncol; 1993; 120(1-2):17-23. PubMed ID: 7903668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
    Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2.
    Duverger V; Sartorius U; Klein-Bauernschmitt P; Krammer PH; Schlehofer JR
    Int J Cancer; 2002 Feb; 97(5):706-12. PubMed ID: 11807802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.
    Marini AM; Fridman R; Kanemoto T; Martin GR; Guo Y; Passaniti A
    J Natl Cancer Inst; 1992 Oct; 84(20):1582-7. PubMed ID: 1328660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
    Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.
    Eisold S; Dihlmann S; Linnebacher M; Ryschich E; Aulmann M; Schmidt J; Schlehofer JR; Ridder R; von Knebel Doeberitz M
    Int J Cancer; 2002 Aug; 100(5):606-14. PubMed ID: 12124812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer].
    Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
    Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
    Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II study of lung cancer--evaluation of new drug in small cell lung cancer (SCLC) and phase II testing of analogues].
    Furuse K
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1499-503. PubMed ID: 1649580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
    Locke VL; Davey RA; Davey MW
    Anticancer Drugs; 2003 Aug; 14(7):523-31. PubMed ID: 12960736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.